IN2013MU01468A - - Google Patents

Info

Publication number
IN2013MU01468A
IN2013MU01468A IN1468MU2013A IN2013MU01468A IN 2013MU01468 A IN2013MU01468 A IN 2013MU01468A IN 1468MU2013 A IN1468MU2013 A IN 1468MU2013A IN 2013MU01468 A IN2013MU01468 A IN 2013MU01468A
Authority
IN
India
Prior art keywords
compound
formula
fatty liver
nonalcoholic
liver
Prior art date
Application number
Other languages
English (en)
Inventor
Pankaj Patel
Jani Rajendrakumar Hariprasad
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201592020A priority Critical patent/EA201592020A1/ru
Priority to US14/782,609 priority patent/US20160166539A1/en
Priority to EP13767126.9A priority patent/EP2988736A1/en
Priority to SG11201506218UA priority patent/SG11201506218UA/en
Priority to JP2016505927A priority patent/JP6246895B2/ja
Priority to AP2015008674A priority patent/AP2015008674A0/xx
Priority to KR1020157024370A priority patent/KR101617812B1/ko
Priority to IN1468MU2013 priority patent/IN2013MU01468A/en
Priority to UAA201509744A priority patent/UA114360C2/uk
Priority to MYPI2015002026A priority patent/MY180160A/en
Priority to CA2900435A priority patent/CA2900435C/en
Priority to MX2015010769A priority patent/MX346943B/es
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2013/000391 priority patent/WO2014174524A1/en
Priority to GEAP201313941A priority patent/GEP201706663B/en
Priority to AU2013387996A priority patent/AU2013387996B2/en
Priority to CN201380075905.9A priority patent/CN105377246B/zh
Priority to BR112015020600A priority patent/BR112015020600A2/pt
Priority to MA38385A priority patent/MA38385A1/fr
Publication of IN2013MU01468A publication Critical patent/IN2013MU01468A/en
Priority to IL240183A priority patent/IL240183A/en
Priority to PH12015501795A priority patent/PH12015501795A1/en
Priority to HK16103017.5A priority patent/HK1214968A1/zh
Priority to IL247231A priority patent/IL247231A/en
Priority to US15/343,859 priority patent/US9814697B2/en
Priority to US15/801,738 priority patent/US20180185330A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1468MU2013 2013-04-22 2013-06-25 IN2013MU01468A (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
US14/782,609 US20160166539A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
GEAP201313941A GEP201706663B (en) 2013-04-22 2013-06-25 Novel composition for nonalcoholic fatty liver disease (nafld
JP2016505927A JP6246895B2 (ja) 2013-04-22 2013-06-25 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）のための新規組成物
AP2015008674A AP2015008674A0 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (NAFLD)
KR1020157024370A KR101617812B1 (ko) 2013-04-22 2013-06-25 비알콜성 지방간 질환을 위한 신규 조성물
IN1468MU2013 IN2013MU01468A (es) 2013-04-22 2013-06-25
UAA201509744A UA114360C2 (uk) 2013-04-22 2013-06-25 Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
MYPI2015002026A MY180160A (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
CA2900435A CA2900435C (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
MX2015010769A MX346943B (es) 2013-04-22 2013-06-25 Una nueva composición para esteatosis hepática no alcohólica (nafld).
EA201592020A EA201592020A1 (ru) 2013-04-22 2013-06-25 Новая композиция для неалкогольной жировой болезни печени (нажбп)
EP13767126.9A EP2988736A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
SG11201506218UA SG11201506218UA (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
AU2013387996A AU2013387996B2 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (NAFLD)
CN201380075905.9A CN105377246B (zh) 2013-04-22 2013-06-25 针对非酒精性脂肪性肝病(nafld)的新组合物
BR112015020600A BR112015020600A2 (pt) 2013-04-22 2013-06-25 composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
MA38385A MA38385A1 (fr) 2013-04-22 2013-06-25 Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
IL240183A IL240183A (en) 2013-04-22 2015-07-28 Non-Alcoholic Obesity Preparation (nafld)
PH12015501795A PH12015501795A1 (en) 2013-04-22 2015-08-14 A novel composition for nonalcoholic fatty liver disease (nafld)
HK16103017.5A HK1214968A1 (zh) 2013-04-22 2016-03-15 用於非酒精性脂肪肝病 的新組合物
IL247231A IL247231A (en) 2013-04-22 2016-08-11 Preparation for the treatment of non-alcoholic obesity
US15/343,859 US9814697B2 (en) 2013-04-22 2016-11-04 Composition for nonalcoholic fatty liver disease (NAFLD)
US15/801,738 US20180185330A1 (en) 2013-04-22 2017-11-02 Novel composition for nonalcoholic fatty liver disease (nafld)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1468MU2013 IN2013MU01468A (es) 2013-04-22 2013-06-25

Publications (1)

Publication Number Publication Date
IN2013MU01468A true IN2013MU01468A (es) 2015-04-17

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1468MU2013 IN2013MU01468A (es) 2013-04-22 2013-06-25

Country Status (21)

Country Link
US (3) US20160166539A1 (es)
EP (1) EP2988736A1 (es)
JP (1) JP6246895B2 (es)
KR (1) KR101617812B1 (es)
CN (1) CN105377246B (es)
AP (1) AP2015008674A0 (es)
AU (1) AU2013387996B2 (es)
BR (1) BR112015020600A2 (es)
CA (1) CA2900435C (es)
EA (1) EA201592020A1 (es)
GE (1) GEP201706663B (es)
HK (1) HK1214968A1 (es)
IL (2) IL240183A (es)
IN (1) IN2013MU01468A (es)
MA (1) MA38385A1 (es)
MX (1) MX346943B (es)
MY (1) MY180160A (es)
PH (1) PH12015501795A1 (es)
SG (1) SG11201506218UA (es)
UA (1) UA114360C2 (es)
WO (1) WO2014174524A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825456C (en) 2011-01-31 2016-01-05 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN105377246B (zh) 2013-04-22 2018-03-20 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
BR112019011740A2 (pt) * 2016-12-09 2019-10-29 Cadila Healthcare Ltd composição farmacêutica e método para o tratamento de colangite biliar primária
CA3055581C (en) 2017-03-28 2023-03-14 Gilead Sciences, Inc. Methods of treating liver disease
WO2019071216A1 (en) 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US20220071954A1 (en) * 2018-12-18 2022-03-10 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL176885B1 (pl) 1992-07-03 1999-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
TW480262B (en) 1995-04-28 2002-03-21 Daiichi Seiyaku Co A taxol derivative having an antitumor activity and a pharmaceutical composition comprising the same
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
EP1082313A1 (en) 1998-05-27 2001-03-14 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
KR100649304B1 (ko) 2000-01-19 2006-11-24 카딜라 헬스케어 리미티드 저지방혈증, 저콜레스테롤혈증 활성을 가지는 신규화합물, 그 제조방법 및 이를 포함하는 제약학적 조성물
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
EP2096170B1 (en) * 2005-09-19 2011-08-10 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
AU2007297388A1 (en) * 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. RNAi modulation of scap and therapeutic uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
ES2681794T3 (es) 2009-11-26 2018-09-17 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
CA2825456C (en) * 2011-01-31 2016-01-05 Cadila Healthcare Limited Treatment for lipodystrophy
CN105377246B (zh) 2013-04-22 2018-03-20 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Also Published As

Publication number Publication date
CA2900435C (en) 2017-02-14
WO2014174524A8 (en) 2015-10-01
CN105377246A (zh) 2016-03-02
EA201592020A1 (ru) 2016-05-31
IL240183A (en) 2016-08-31
MX346943B (es) 2017-04-06
AP2015008674A0 (en) 2015-08-31
EP2988736A1 (en) 2016-03-02
BR112015020600A2 (pt) 2017-07-18
US20180185330A1 (en) 2018-07-05
US20160166539A1 (en) 2016-06-16
MX2015010769A (es) 2015-11-26
AU2013387996A1 (en) 2015-09-24
SG11201506218UA (en) 2015-09-29
CA2900435A1 (en) 2014-10-30
UA114360C2 (uk) 2017-05-25
US20170087127A1 (en) 2017-03-30
KR101617812B1 (ko) 2016-05-03
JP6246895B2 (ja) 2017-12-13
AU2013387996B2 (en) 2015-12-10
HK1214968A1 (zh) 2016-08-12
JP2016515608A (ja) 2016-05-30
CN105377246B (zh) 2018-03-20
KR20150118990A (ko) 2015-10-23
MA38385A1 (fr) 2017-09-29
PH12015501795A1 (en) 2015-11-09
MY180160A (en) 2020-11-23
WO2014174524A1 (en) 2014-10-30
IL240183A0 (en) 2015-09-24
GEP201706663B (en) 2017-05-10
IL247231A (en) 2017-03-30
US9814697B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
PH12015501795A1 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
EA032971B1 (ru) Соль берберина и урсодезоксихолевой кислоты и ее применение
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
NZ726366A (en) Syk inhibitors
MX349159B (es) Derivados deuterados de ivacaftor.
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MY178621A (en) Deuterated cftr potentiators
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
MX2015004771A (es) Metodos para tratar cancer.
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
PH12016502352A1 (en) Pharmaceutical composition
BR112016024020A2 (pt) composição farmacêutica
MX2012012095A (es) Analogos de tiazolidinadiona.
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
EA201291384A1 (ru) Терапевтические агенты 976
PH12016501553B1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
NZ701995A (en) Therapeutic biologic for treatment of hepatocellular carcinoma